Commonwealth Equity Services LLC Makes New Investment in Natera, Inc. (NASDAQ:NTRA)

Commonwealth Equity Services LLC acquired a new stake in Natera, Inc. (NASDAQ:NTRAFree Report) in the 1st quarter, according to the company in its most recent filing with the SEC. The firm acquired 15,222 shares of the medical research company’s stock, valued at approximately $1,392,000.

Several other hedge funds have also recently modified their holdings of the company. Allspring Global Investments Holdings LLC boosted its holdings in shares of Natera by 28.6% in the 4th quarter. Allspring Global Investments Holdings LLC now owns 720,160 shares of the medical research company’s stock worth $45,111,000 after buying an additional 159,993 shares during the last quarter. Cerity Partners LLC grew its position in shares of Natera by 1,043.3% during the 4th quarter. Cerity Partners LLC now owns 90,423 shares of the medical research company’s stock valued at $5,664,000 after acquiring an additional 82,514 shares during the period. WCM Investment Management LLC increased its stake in shares of Natera by 101.2% during the 4th quarter. WCM Investment Management LLC now owns 145,996 shares of the medical research company’s stock worth $9,058,000 after purchasing an additional 73,419 shares during the last quarter. Thematics Asset Management raised its holdings in shares of Natera by 3.1% in the 4th quarter. Thematics Asset Management now owns 90,232 shares of the medical research company’s stock worth $5,652,000 after purchasing an additional 2,738 shares during the period. Finally, Crestline Management LP lifted its stake in Natera by 16.0% in the fourth quarter. Crestline Management LP now owns 65,070 shares of the medical research company’s stock valued at $4,076,000 after purchasing an additional 8,997 shares during the last quarter. Institutional investors own 99.90% of the company’s stock.

Natera Stock Performance

Shares of NASDAQ NTRA opened at $112.74 on Friday. The company has a debt-to-equity ratio of 0.36, a current ratio of 4.12 and a quick ratio of 3.98. The business has a 50-day moving average of $106.53 and a 200-day moving average of $87.63. Natera, Inc. has a 12 month low of $36.90 and a 12 month high of $117.23.

Natera (NASDAQ:NTRAGet Free Report) last released its quarterly earnings results on Thursday, May 9th. The medical research company reported ($0.56) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.16. Natera had a negative net margin of 30.24% and a negative return on equity of 49.72%. The business had revenue of $367.70 million during the quarter, compared to analysts’ expectations of $316.31 million. During the same quarter in the previous year, the company earned ($1.23) EPS. The business’s quarterly revenue was up 52.1% compared to the same quarter last year. As a group, sell-side analysts expect that Natera, Inc. will post -2.43 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages recently issued reports on NTRA. Canaccord Genuity Group boosted their price objective on Natera from $100.00 to $130.00 and gave the company a “buy” rating in a research note on Friday, May 10th. Jefferies Financial Group initiated coverage on shares of Natera in a research note on Monday, June 3rd. They set a “buy” rating and a $142.00 price target on the stock. Piper Sandler raised their price objective on shares of Natera from $110.00 to $120.00 and gave the stock an “overweight” rating in a report on Tuesday, May 14th. TD Cowen boosted their target price on shares of Natera from $123.00 to $137.00 and gave the company a “buy” rating in a report on Friday, May 10th. Finally, Craig Hallum started coverage on Natera in a report on Monday, April 8th. They issued a “buy” rating and a $117.00 price target for the company. One investment analyst has rated the stock with a hold rating and sixteen have given a buy rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $101.19.

Get Our Latest Research Report on NTRA

Insider Transactions at Natera

In related news, insider Solomon Moshkevich sold 80,000 shares of the firm’s stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $90.82, for a total transaction of $7,265,600.00. Following the transaction, the insider now directly owns 117,560 shares of the company’s stock, valued at approximately $10,676,799.20. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. In other Natera news, CEO Steven Leonard Chapman sold 6,816 shares of the company’s stock in a transaction dated Monday, April 15th. The shares were sold at an average price of $93.13, for a total transaction of $634,774.08. Following the completion of the sale, the chief executive officer now directly owns 227,710 shares in the company, valued at $21,206,632.30. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Also, insider Solomon Moshkevich sold 80,000 shares of Natera stock in a transaction dated Tuesday, April 16th. The stock was sold at an average price of $90.82, for a total value of $7,265,600.00. Following the completion of the transaction, the insider now owns 117,560 shares in the company, valued at approximately $10,676,799.20. The disclosure for this sale can be found here. In the last three months, insiders sold 201,770 shares of company stock worth $20,023,161. 7.60% of the stock is currently owned by corporate insiders.

Natera Company Profile

(Free Report)

Natera, Inc, a diagnostics company, develops and commercializes molecular testing services worldwide. Its products include Panorama, a non-invasive prenatal test that screens for chromosomal abnormalities of a fetus, as well as in twin pregnancies; Horizon carrier screening test for individuals and couples determine if they are carriers of genetic variations that cause certain genetic conditions; Vistara single-gene NIPT screens for 25 single-gene disorders that cause severe skeletal, cardiac, and neurological conditions; Spectrum, preimplantation genetic tests for couples undergoing IVF; Anora that analyzes miscarriage tissue from women; Empower, a hereditary cancer screening test; and non-invasive prenatal paternity product, which allows a couple to establish paternity without waiting for the child to be born.

See Also

Want to see what other hedge funds are holding NTRA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Natera, Inc. (NASDAQ:NTRAFree Report).

Institutional Ownership by Quarter for Natera (NASDAQ:NTRA)

Receive News & Ratings for Natera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natera and related companies with MarketBeat.com's FREE daily email newsletter.